CoChat
Sign Up
Cited by 1,463Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug ReactionsMuscle and Compartmental Disorders

The DOI matches its Crossref record; 103 of the 114 references it cites were found in a registry or an index.

Statin-Associated Myopathy

Thompson, Paul D., Clarkson, Priscilla, Karas, Richard H.·2003·JAMA
DOI 10.1001/jama.289.13.1681
Open this paper in CoChat — free account

Abstract

Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are associated with skeletal muscle complaints, including clinically important myositis and rhabdomyolysis, mild serum creatine kinase (CK) elevations, myalgia with and without elevated CK levels, muscle weakness, muscle cramps, and persistent myalgia and CK elevations after statin withdrawal. We performed a literature review to provide a clinical summary of statin-associated myopathy and discuss possible mediating mechanisms. We also update the US Food and Drug Administration (FDA) reports on statin-associated rhabdomyolysis. Articles on statin myopathy were identified via a PubMed search through November 2002 and articles on statin clinical trials, case series, and review articles were identified via a PubMed search through January 2003. Adverse event reports of statin-associated rhabdomyolysis were also collected from the FDA MEDWATCH database. The literature review found that reports of muscle problems during statin clinical trials are extremely rare. The FDA MEDWATCH Reporting System lists 3339 cases of statin-associated rhabdomyolysis reported between January 1, 1990, and March 31, 2002. Cerivastatin was the most commonly implicated statin. Few data are available regarding the frequency of less-serious events such as muscle pain and weakness, which may affect 1% to 5% of patients. The risk of rhabdomyolysis and other adverse effects with statin use can be exacerbated by several factors, including compromised hepatic and renal function, hypothyroidism, diabetes, and concomitant medications. Medications such as the fibrate gemfibrozil alter statin metabolism and increase statin plasma concentration. How statins injure skeletal muscle is not clear, although recent evidence suggests that statins reduce the production of small regulatory proteins that are important for myocyte maintenance.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.289.13.1681

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 114 references

Research works printed but not linked: 9

  1. Fuhrmans, 2002, Bayer discloses higher death toll from Baycol., Wall Street Journal, A10
  2. Hamilton-Craig, 2001, Statin-associated myopathy., Med J Aust, 175, 486, 10.5694/mja2.2001.175.issue-9 · DOI
  3. Omar, 2002, FDA adverse event reports on statin-associated rhabdomyolysis., Ann Pharmacother, 36, 288, 10.1345/aph.1A289 · DOI · Paper page
  4. GISSI Prevenzione Investigators, 2000, Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico)?, Ital Heart J, 1, 810
  5. Omar, 2001, Rhabdomyolysis and HMG-CoA reductase inhibitors., Ann Pharmacother, 35, 1096, 10.1345/aph.10228 · DOI · Paper page
  6. Shek, 2001, Statin-fibrate combination therapy., Ann Pharmacother, 35, 908, 10.1345/aph.10315 · DOI · Paper page
  7. Prueksaritanont, 2002, Metabolic interactions between gemfibrozil and statins in human liver preparations [abstract]., Circulation, 106, II185
  8. Not Available, 2001, Cardiovascular Trials Review
  9. Not Available, 2002, Cardiovascular Trials Review

Cited by

Sorted by citations

Items 701–800 of 1,001

Related

See all

Metadata

Authors
Thompson, P. D., Clarkson, P., & Karas, R. H.
Affiliations
Hartford Hospital (US)
ORCID
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2003-04-02
Volume
289
Issue
13
Pages
1681
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.289.13.1681
OpenAlex
W2059078444
Cited by
1,463
References
114
Citations by year
2026: 8 · 2025: 22 · 2024: 31 · 2023: 27 · 2022: 30 · 2021: 33 · 2020: 38 · 2019: 54 · 2018: 52 · 2017: 54 · 2016: 79 · 2015: 60 · 2014: 76 · 2013: 75 · 2012: 97
FWCI
19.53
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
  • ScholarWorks@UMassAmherst (University of Massachusetts Amherst) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Surgery › Muscle and Compartmental Disorders
Keywords
statin-induced myopathy, statins, rhabdomyolysis, myositis, creatine kinase elevation, myalgia, statin withdrawal, adverse drug reactions, cerivastatin, gemfibrozil, drug interactions
MeSH terms
Anticholesteremic Agents, Creatine Kinase, Humans, Muscle Cramp, Muscular Diseases, Myositis, Rhabdomyolysis, Adverse Drug Reaction Reporting Systems, Muscle, Skeletal, Muscle Weakness, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review